만성 간질환에서 항섬유화 치료의 과거와 미래
Year: 2006
Type: article
Abstract: Hepatic fibrosis is characterized by the excessive accumulation of multiple matrix
components in the liver including the interstitial collagens, basement membrane collagens,
proteoglycans, and matrix glycoproteins. Activated hepatic stellate cells, portal fibroblasts, and
myofibroblasts are the major source of extracellular matrix in response to fibrogenic cytokines
such as TGF- . The fibrogenic process is dynamic and liver fibrosis is the net result of β
the imbalance between the collagen fiber synthesis and decomposition. The progress in
understanding fibrogenic mechanism provided the development of effective therapies to reverse
hepatic fibrosis and even cirrhosis. Removing the injurious stimuli, suppressing hepatic
inflammation, down-regulating stellate cell activation and promoting matrix degradation are
the mainstay of antifibrotic therapy. Many potential antifibrotic strategies based on apoptosis
of the activated stellate cells, drug targeting to the fibrogenic liver cells, and combination
therapy of multiple drugs in small doses are emerging but testing of their clinical efficacy and
safety remains to be clarified.
Author: 이영석
Language: Korean
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $32
OpenAlex ID: W3177230149